Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

Featuring proceedings from a live event on January 9, 2026, held adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium and moderated by Dr Samuel J Klempner, including the following topics:

• Treatment approach for metastatic HER2-negative, claudin 18.2-positive, microsatellite instability-high gastroesophageal (GE) cancer (0:00)
• Duration of chemotherapy for patients with advanced GE cancers receiving nivolumab/chemotherapy (3:06)
• Younger patient with metastatic PD-L1-positive gastric cancer (5:29)

CME information and select publications